By Pietro Lombardi

Bayer AG has reached an agreement to buy research and development company Noria Therapeutics Inc. and its subsidiary PSMA Therapeutics Inc. in a move that broadens its prostate cancer portfolio.

The target companies, based in New York, have exclusive global rights to technology licensed from Weill Cornell Medicine and Johns Hopkins University, the German pharmaceutical and chemical conglomerate said Thursday.

Financial details of the deal weren't disclosed.

Write to Pietro Lombardi at pietro.lombardi@wsj.com; @pietrolombard10

(END) Dow Jones Newswires

June 03, 2021 08:28 ET (12:28 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bayer Charts.
Bayer (TG:BAYN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bayer Charts.